Insmed, Inc. INSM
Analyst Ratings
- Consensus
- Buy — 20 Buy · 0 Hold · 0 Sell (20 analysts)
- Avg. Price Target
- $208.70 (+61.3% upside)
Key Stats
- Today's Range
- $126.52 – $130.25
- 50-Day Range
- $96.42 – $137.70
- 52-Week Range
- $90.39 – $212.75
- Volume
- 1.70 million shs
- Average Volume
- 2.65 million shs
- Market Cap
- $28.26 billion
- P/E Ratio
- —
- Dividend Yield
- —
Valuation
- P/E Ratio
- —
- Price / Book
- 37.31
- Price / Sales
- 24.84
Short Interest
- Short Interest
- 2.48%
- Days to Cover
- 8.90
Financials (TTM)
- Revenue
- $1.14 billion
- Net Income
- $-875,311,000
- Net Margin
- -76.94%
- Return on Equity
- -115.55%
- Debt-to-Equity
- 0.72
About Insmed, Inc.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
Related Stocks
Compare head-to-head: INSM vs LLY·INSM vs JNJ·INSM vs ABBV·INSM vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.